Aurora Spine Corporation (ASAPF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Aurora Spine Corporation (ASAPF) with AI Score 48/100 (Weak). Aurora Spine Corporation develops and distributes minimally invasive interspinous fusion systems and devices. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Aurora Spine Corporation (ASAPF) Healthcare & Pipeline Overview
Aurora Spine Corporation, a Canadian medical device company, specializes in minimally invasive spinal fusion technologies, including interspinous fusion devices and interbody cages, targeting patients with degenerative disc diseases. With a focus on innovation and 3D-printed implants, Aurora Spine operates within the competitive medical device landscape.
Investment Thesis
Aurora Spine Corporation presents a focused investment opportunity within the medical device sector, specifically targeting the spinal fusion market. The company's emphasis on minimally invasive techniques and innovative products like the SOLO and DEXA-C devices could drive future growth. With a market capitalization of $0.02 billion, Aurora Spine operates with a negative P/E ratio of -11.66 and a negative profit margin of -7.4%, indicating potential for improved profitability. A gross margin of 59.7% suggests efficient production and pricing strategies. Key catalysts include expanding distribution networks and securing regulatory approvals for new products. However, investors should be aware of the risks associated with the OTC market and the company's current financial performance.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.02 billion indicates a small-cap company with potential for growth.
- Negative P/E ratio of -11.66 reflects current unprofitability, suggesting potential for future earnings improvement.
- Gross margin of 59.7% demonstrates efficient cost management in product manufacturing and sales.
- Beta of -0.54 suggests the stock is less volatile than the market, potentially offering stability during market downturns.
- Focus on minimally invasive spinal fusion technologies positions the company in a growing segment of the medical device market.
Competitors & Peers
Strengths
- Innovative interspinous fusion technology.
- Focus on minimally invasive solutions.
- 3D-printing capabilities for customized implants.
- Established distribution network in Canada.
Weaknesses
- Limited market presence outside of Canada.
- Negative profitability and reliance on external funding.
- Small market capitalization and limited resources.
- Dependence on key product lines.
Catalysts
- Upcoming: FDA approval for key products (ZIP, SOLO) for US market entry.
- Upcoming: Strategic partnerships with hospitals and surgical centers to expand distribution.
- Ongoing: Increasing adoption of 3D-printed implants in spinal fusion procedures.
- Ongoing: Development and launch of new spinal fusion technologies.
- Ongoing: Expansion of sales and marketing efforts in the Canadian market.
Risks
- Potential: Competition from larger medical device companies with greater resources.
- Potential: Regulatory hurdles and delays in obtaining FDA approvals.
- Potential: Product liability and litigation risks associated with spinal implants.
- Ongoing: Negative profitability and reliance on external funding.
- Ongoing: Limited market presence outside of Canada.
Growth Opportunities
- Expansion into the US Market: Aurora Spine has the opportunity to expand its market reach into the United States, a significantly larger market for spinal implants. Securing FDA approval for its key products, such as the ZIP and SOLO systems, would be crucial for this expansion. The US spinal implant market is estimated to be worth billions of dollars annually, offering substantial revenue potential for Aurora Spine. Timeline: 2-3 years for regulatory approvals and market entry.
- Increased Adoption of 3D-Printed Implants: Aurora Spine's DEXA-C cervical interbody system, which utilizes 3D-printed technology, presents a growth opportunity. As 3D printing becomes more prevalent in medical device manufacturing, Aurora Spine can capitalize on the demand for customized and porous implants that promote bone growth. The 3D-printed medical device market is experiencing rapid growth, driven by its ability to create patient-specific solutions. Timeline: Ongoing, with increasing adoption over the next 5 years.
- Strategic Partnerships and Distribution Agreements: Forming strategic partnerships with hospitals, surgical centers, and distributors can accelerate Aurora Spine's market penetration. Collaborations with established players in the medical device industry can provide access to wider distribution networks and increased brand visibility. These partnerships can also facilitate the adoption of Aurora Spine's products by surgeons and healthcare providers. Timeline: 1-2 years to establish key partnerships.
- Development of New Spinal Fusion Technologies: Investing in research and development to create new and innovative spinal fusion technologies can drive future growth. Focusing on areas such as motion preservation, regenerative medicine, and personalized implants can differentiate Aurora Spine from its competitors. Continuous innovation is essential for maintaining a competitive edge in the rapidly evolving medical device industry. Timeline: Ongoing, with new product launches every 2-3 years.
- Focus on Minimally Invasive Surgical Techniques: The increasing demand for minimally invasive surgical procedures presents a growth opportunity for Aurora Spine. The company's ZIP system and other interspinous fusion devices align with this trend, offering patients less invasive alternatives to traditional spinal fusion. As more surgeons adopt minimally invasive techniques, the demand for Aurora Spine's products is expected to increase. Timeline: Ongoing, with increasing adoption over the next 5 years.
Opportunities
- Expansion into the US market.
- Increased adoption of 3D-printed implants.
- Strategic partnerships and distribution agreements.
- Development of new spinal fusion technologies.
Threats
- Competition from larger medical device companies.
- Regulatory hurdles and approval processes.
- Product liability and litigation risks.
- Economic downturns and healthcare spending cuts.
Competitive Advantages
- Proprietary interspinous fusion technology (ZIP system).
- Focus on minimally invasive surgical techniques.
- 3D-printed implant capabilities (DEXA-C).
- Established presence in the Canadian market.
About ASAPF
Aurora Spine Corporation, established in 2013 and headquartered in Toronto, Canada, operates through its subsidiary, Aurora Spine, Inc., focusing on the design, development, and commercialization of minimally invasive spinal implant systems. The company's core business revolves around addressing spinal pathologies through innovative interspinous fusion and interbody technologies. Their product portfolio includes a range of interspinous process lumbar fusion devices like the ZIP family (ZIP, ZIP ULTRA, ZIP LP, and ZIP-51), designed to alleviate pain and stabilize the spine in patients with degenerative disc diseases. These devices offer a less invasive alternative to traditional spinal fusion surgeries. In addition to interspinous devices, Aurora Spine offers Ti-Coated polyether ether ketone (PEEK) interbody cages, which provide structural support and promote bone growth between vertebrae during fusion. The company also provides sterile-packed titanium plasma spray coated spinal infusion implants. Their interbody product line includes EOS, VOX, Echo, Echo SD, and EchoXL for lumbar applications, and Discovery for cervical procedures. Aurora Spine has also introduced SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device, and SiLo, a posterior fusion device for the sacroiliac joint. Further expanding their offerings, DEXA-C, a cervical interbody system, utilizes porous 3D-printed intervertebral body fusion devices with customizable lattice patterns to match individual patient bone quality. Aurora Spine primarily serves the Canadian market, focusing on providing advanced spinal solutions to improve patient outcomes and quality of life.
What They Do
- Develops minimally invasive interspinous fusion systems.
- Distributes spinal implants and devices.
- Offers interspinous process lumbar fusion devices (ZIP, ZIP ULTRA, ZIP LP, ZIP-51).
- Provides Ti-Coated polyether ether ketone interbody cages.
- Manufactures sterile-packed titanium plasma spray coated spinal infusion implants.
- Offers interbody products (EOS, VOX, Echo, Echo SD, EchoXL, Discovery).
- Provides SOLO, an anterior lumbar interbody fusion 3D printed stand-alone fusion device.
- Offers SiLo, a posterior fusion device for the sacroiliac joint.
Business Model
- Develops and manufactures spinal implants and devices.
- Sells products directly to hospitals and surgical centers.
- Utilizes distributors to reach a wider customer base.
- Generates revenue through the sale of its spinal fusion products.
Industry Context
Aurora Spine Corporation operates within the medical device industry, specifically focusing on spinal implants and fusion technologies. The global spinal implants and surgery devices market is projected to reach billions of dollars by 2026, driven by an aging population, increasing prevalence of spinal disorders, and advancements in minimally invasive surgical techniques. The competitive landscape includes established players like BTCY, CLCS, EMITF, GTHP, and IMMVF, as well as larger medical device companies. Aurora Spine differentiates itself through its focus on innovative designs, 3D-printed implants, and interspinous fusion devices.
Key Customers
- Hospitals
- Surgical centers
- Spinal surgeons
- Patients suffering from degenerative disc diseases
Financials
Chart & Info
Aurora Spine Corporation (ASAPF) stock price: Price data unavailable
Latest News
No recent news available for ASAPF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASAPF.
Price Targets
Wall Street price target analysis for ASAPF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ASAPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Trent J. Northcutt
Unknown
Information on Trent J. Northcutt's background is not available in the provided context. Further research would be needed to provide details on his career history, education, and previous roles.
Track Record: Information on Trent J. Northcutt's track record is not available in the provided context. Further research would be needed to provide details on key achievements, strategic decisions, and company milestones under his leadership.
ASAPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Aurora Spine Corporation may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting, making it more difficult for investors to assess their financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries higher risks due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Higher risk of price manipulation.
- Potential for delisting or suspension of trading.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor trading volume and price volatility.
- Consult with a financial advisor.
- Company has been in operation since 2013.
- Focus on developing and distributing medical devices.
- Presence of a physical headquarters in Toronto, Canada.
- Product portfolio includes multiple spinal fusion devices.
What Investors Ask About Aurora Spine Corporation (ASAPF)
What does Aurora Spine Corporation do?
Aurora Spine Corporation is a medical device company specializing in the design, development, and commercialization of minimally invasive spinal implant systems. The company's primary focus is on providing solutions for patients suffering from degenerative disc diseases and other spinal conditions. Their product portfolio includes interspinous fusion devices, interbody cages, and 3D-printed implants, all designed to improve patient outcomes and quality of life. Aurora Spine primarily serves the Canadian market, offering advanced spinal solutions to hospitals, surgical centers, and spinal surgeons.
What do analysts say about ASAPF stock?
As of 2026-03-16, formal analyst ratings for Aurora Spine Corporation (ASAPF) are limited due to its OTC listing and small market capitalization. Key valuation metrics include a negative P/E ratio, reflecting current unprofitability, and a gross margin of 59.7%, indicating efficient cost management. Growth considerations center on the company's ability to expand into the US market, secure regulatory approvals, and increase adoption of its innovative spinal fusion technologies. Investors should conduct their own due diligence and consider the risks associated with OTC-listed stocks.
What are the main risks for ASAPF?
Aurora Spine Corporation faces several risks, including competition from larger medical device companies, regulatory hurdles in obtaining FDA approvals for US market expansion, and potential product liability claims associated with spinal implants. The company's negative profitability and reliance on external funding also pose financial risks. Additionally, its limited market presence outside of Canada and dependence on key product lines could impact future growth. Investors should carefully consider these risks before investing in ASAPF.
What are the key factors to evaluate for ASAPF?
Aurora Spine Corporation (ASAPF) currently holds an AI score of 48/100, indicating low score. Key strength: Innovative interspinous fusion technology.. Primary risk to monitor: Potential: Competition from larger medical device companies with greater resources.. This is not financial advice.
How frequently does ASAPF data refresh on this page?
ASAPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ASAPF's recent stock price performance?
Recent price movement in Aurora Spine Corporation (ASAPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Innovative interspinous fusion technology.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ASAPF overvalued or undervalued right now?
Determining whether Aurora Spine Corporation (ASAPF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ASAPF?
Before investing in Aurora Spine Corporation (ASAPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on CEO's background and track record.
- OTC market stocks carry higher risk than exchange-listed stocks.